Therapeutic anticoagulation after liver transplantation is not useful among patients with pre‐transplant Yerdel‐grade I/II portal vein thrombosis: A two‐center retrospective study

Autor: Isabel Bos, Marc Blondeau, Michel Rayar, Dune Wouters, Willemijn van der Plas, Christophe Camus, Vincent E de Meijer, Pauline Houssel-Debry, Robert J. Porte, Lianne M Nieuwenhuis, Edouard Bardou-Jacquet, Ton Lisman
Přispěvatelé: Groningen Institute for Organ Transplantation (GIOT), Center for Liver, Digestive and Metabolic Diseases (CLDM)
Rok vydání: 2021
Předmět:
Zdroj: Journal of Thrombosis and Haemostasis, 19(11), 2760-2771. Wiley
ISSN: 1538-7836
1538-7933
DOI: 10.1111/jth.15472
Popis: BACKGROUND: Portal vein thrombosis (PVT) is no longer a contraindication for liver transplantation (LT). While therapeutic anticoagulation (tAC) is recommended during the waiting period, there is no evidence for its usefulness in the prevention of PVT recurrence after LT.OBJECTIVES: The aim of our study was to evaluate the role of tAC post-LT in the prevention of PVT recurrence.PATIENTS/METHODS: All adult LTs performed in 2 high volume centres between 2003 and 2018, were retrospectively analysed. Only patients with PVT classified as Yerdel grade I or II and with standard portal reconstruction were included. PVT recurrence and tAC-associated morbidity within 1 year were compared between patients receiving tAC or not.RESULTS: During the study period, out of 2612 LTs performed, 235 (9%) patients with PVT were included. 113 patients (48.1%) received post-LT tAC (tAC group) while 122 (51.9%) did not (non-tAC group). The incidence of bleeding events was significantly higher in the tAC group (26 (23%) vs. 5 (4.1%), pCONCLUSION: Therapeutic anticoagulation is not necessary in the prevention of grade I/II PVT recurrence and is associated with higher morbidity and longer hospital stay.
Databáze: OpenAIRE